BORA - UiB

Bergen Open Research Archive

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

Bergen Open Research Archive

Show simple item record

dc.contributor.author Zubac, Dragomir
dc.contributor.author Wentzel-Larsen, Tore
dc.contributor.author Seidal, Tomas
dc.contributor.author Bostad, Leif
dc.date.accessioned 2011-04-08T06:35:30Z
dc.date.available 2011-04-08T06:35:30Z
dc.date.issued 2010-12-03
dc.identifier.citation BMC Urology 10:20 en_US
dc.identifier.issn 1471-2490
dc.identifier.uri http://dx.doi.org/10.1186/1471-2490-10-20
dc.identifier.uri http://hdl.handle.net/1956/4635
dc.description.abstract Background To examine the expression of type 1 plasminogen inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC), and its possible association with microvessel density (MVD), the expression of thrombospondin-1 (TSP-1), nuclear grade, tumour stage, continuously coded tumour size (CCTS) and to assess the value of PAI as a prognostic marker in 162 patients with CCRCC treated with radical nephrectomy. Methods A total of 172 consecutive patients with CCRCC treated with radical nephrectomy were enrolled in the study. The expression of PAI-1, TSP-1 and factor VIII were analysed on formalin-fixed, paraffin-embedded tissues without knowledge of the clinical outcome. Ten cases, where PAI-1 immunohistochemistry was not possible due to technical problems and lack of material, were excluded. Sixty-nine patients (43%) died of RCC, while 47 patients (29%) died of other diseases. Median follow-up was 13.8 years for the surviving 46 patients (28%). Results Nine percent of the tumours showed PAI-1 positivity. High expression of PAI-1 was significantly inversely correlated with TSP-1 (p = 0.046) and directly with advanced stage (p = 0.008), high NG (3+4) (p = 0.002), tumour size (p = 0.011), microvessel density (p = 0.049) and disease progression (p = 0.002). In univariate analysis PAI-1 was a significant prognosticator of cancer-specific survival (CSS) (p < 0.001). Multivariate analysis revealed that TNM stage (p < 0.001), PAI-1 (p = 0.020), TSP-1 (p < 0.001) and MVD (p = 0.007) were independent predictors of CSS. Conclusions PAI-1 was found to be an independently significant prognosticator of CSS and a promoter of tumour angiogenesis, aggressiveness and progression in CCRCC. en_US
dc.publisher BioMed Central en
dc.rights Copyright 2010 Zubac et al; licensee BioMed Central Ltd. en_US
dc.rights.uri http://creativecommons.org/licenses/by/2.0 en_US
dc.title Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy en_US
dc.type Journal article en_US
dc.type Peer reviewed en_US
dc.subject.nsi VDP::Medical disciplines: 700 en_US
dc.rightsHolder Zubac et al. en_US
dc.type.version publishedVersion en_US


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Copyright 2010 Zubac et al; licensee BioMed Central Ltd. Except where otherwise noted, this item's license is described as Copyright 2010 Zubac et al; licensee BioMed Central Ltd.

Search BORA


Browse

My Account